NDA/BLA filedconf 0.95

adx-2191 — NDA/BLA filed

$ALDX · Aldeyra Therapeutics, Inc. · primary vitreoretinal lymphoma

Event date

Date TBD

Sponsor runway

38 mo

$65.0M liquid

Evidence

“FDA Accepts for Priority Review ADX-2191 New Drug Application for the Treatment of Primary Vitreoretinal Lymphoma”

Source: Press release · 2023-03-02View press release ↗

Ticker	Drug	Date	Outcome
$ALDX	adx-2191	2023-03-02	unknown

3 insiders · 2 buys · 0 sells

Grant

2026-03-27

Brady Todd C

President and CEO

1,880,510 @ ——

Grant

2026-03-27

Brady Todd C

President and CEO

632,318 @ ——

Buy

2026-03-19

DOUGLAS RICHARD

Director

70,000 @ $1.40$98K

Buy

2026-03-18

Alfieri Michael

Principal Financial Officer

5,000 @ $1.42$7K

Date	Insider	Action	Shares	Price	Value
2026-03-27	Brady Todd CPresident and CEO	Grant	1,880,510	—	—
2026-03-27	Brady Todd CPresident and CEO	Grant	632,318	—	—
2026-03-19	DOUGLAS RICHARDDirector	Buy	70,000	$1.40	$98K
2026-03-18	Alfieri MichaelPrincipal Financial Officer	Buy	5,000	$1.42	$7K